<DOC>
	<DOCNO>NCT00927459</DOCNO>
	<brief_summary>This study Phase 1 , single-center , placebo-controlled , single-blind , first-in-human , single-ascending dose study male female subject high cholesterol . A maximum 32 subject plan enrollment study .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics ( PK ) , Pharmacodynamics ( PD ) Liposomal siRNA Subjects With High Cholesterol</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Fasting , stable LDLC ≥ 160 mg/dL Fasting , stable triglyceride &lt; 400 mg/dL BMI 22 35 kg/m2 , inclusive Females must nonchild bear potential Males reproductive potential must agree practice effective contraception throughout study 3 month follow infusion Clinically significant endocrine , hematologic , renal , hepatic , pulmonary , uncontrolled psychiatric , neurologic disease Cancer within 5 year prior screen History congestive heart failure chronic heart failure Uncontrolled cardiac arrhythmias History coronary heart disease Clinically significant abnormal baseline ECG History additional risk factor torsades de pointes Hepatitis B , C , HIV positive Current diagnosis know history liver disease A mark baseline prolongation QT/QTc interval Known history fibromyalgia , myopathy , myositis , rhabdomyolysis , unexplained muscle pain , creatine phosphokinase ( CPK ) &gt; 3 x upper limit normal ( ULN ) screen Alanine aminotransferase , AST , GGT , total bilirubin &gt; 2 x ULN screen Serum creatinine &gt; 1.5 mg/dL Systolic blood pressure ≥ 160 mmHg diastolic blood pressure ≥ 100 mmHg 2 occasion screen Concomitant use medication prolongs QT/QTc interval Treatment lipid lower therapy within 30 day prior screen Use investigational drug within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>cholesterol</keyword>
	<keyword>coronary artery disease</keyword>
</DOC>